Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (13218)	9/30/2004 9:25:41 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

Whatever happened to Bextra? Is it actively promoted?

To: Biomaven who wrote (13218)	9/30/2004 10:48:21 AM
From: NeuroInvestment	Read Replies (1) \| Respond to of 52153

<<I'm pretty impressed by MRK's actions here - not many companies would have done what they are doing. It's a devastating blow to them, and it's going to hurt all the pharmas - going to make people look skeptically at all the cox-2 drugs.>> Peter: Frankly, what choice did they have? They are already likely to face the kind of litigation feeding frenzy that we saw with Redux/AHP--actually far larger, since they have sold so much more of it to so many--and they can be accused of ignoring warnings for quite a while already. If they had ignored this data and continued selling Vioxx? It would have been corporate suicide. Harry NeuroInvestment